Charles Schwab Investment Management Inc. Purchases 32,393 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Charles Schwab Investment Management Inc. boosted its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 36.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,019 shares of the company’s stock after acquiring an additional 32,393 shares during the period. Charles Schwab Investment Management Inc. owned 0.17% of Kiniksa Pharmaceuticals worth $2,414,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after purchasing an additional 1,004 shares during the last quarter. Franklin Resources Inc. increased its position in Kiniksa Pharmaceuticals by 1.7% in the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock worth $1,798,000 after buying an additional 1,100 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Kiniksa Pharmaceuticals by 12.4% during the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock worth $302,000 after buying an additional 1,680 shares during the last quarter. Quarry LP acquired a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $50,000. Finally, Martingale Asset Management L P boosted its position in shares of Kiniksa Pharmaceuticals by 6.8% in the third quarter. Martingale Asset Management L P now owns 48,460 shares of the company’s stock valued at $1,211,000 after acquiring an additional 3,083 shares during the period. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Trading Down 1.2 %

KNSA opened at $23.09 on Friday. The stock has a market cap of $1.68 billion, a PE ratio of -164.92 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $16.56 and a 1 year high of $28.15. The stock’s 50 day simple moving average is $20.77 and its 200-day simple moving average is $22.00.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The business had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company’s quarterly revenue was up 46.9% compared to the same quarter last year. During the same period last year, the firm earned $0.35 EPS. Equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on KNSA shares. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a “buy” rating and a $40.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $37.17.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total transaction of $205,104.90. Following the completion of the transaction, the chief financial officer now directly owns 23,382 shares of the company’s stock, valued at approximately $540,124.20. This trade represents a 27.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Eben Tessari sold 14,000 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the sale, the chief operating officer now owns 81,975 shares of the company’s stock, valued at $1,604,250.75. This trade represents a 14.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 93,766 shares of company stock valued at $2,011,735 over the last quarter. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.